Abstract
Eight peptides were isolated from Bothrops moojeni venom by filtration followed by HPLC. MALDI mass spectroscopy and Edman degradation determined the purity, Mr and sequence of the peptides, respectively. Three (BmP7, BmP8 and BmvP11) of them were homologues with the biologically active B. jararaca bradykinin potentiating peptides while the other with peptides or protein from different sources.
Keywords: Bothrops moojeni, BRADYKININ, algesic hypotensive substance, Kininogenases, angiotensin I to II, angiotensin convertase, antihypertensive drugs, bradykinin potentiating peptides (BPPs)
Protein & Peptide Letters
Title: Bothrops Moojeni Venom Peptides Containing Bradykinin Potentiating Peptides Sequences
Volume: 8 Issue: 1
Author(s): S. C. Bourguignon, F. S. Paes, E. B. Calheiros, M. Juliano, A. S. Aguiar, A. R. Melgarejo and S. Giovanni-De-Simone
Affiliation:
Keywords: Bothrops moojeni, BRADYKININ, algesic hypotensive substance, Kininogenases, angiotensin I to II, angiotensin convertase, antihypertensive drugs, bradykinin potentiating peptides (BPPs)
Abstract: Eight peptides were isolated from Bothrops moojeni venom by filtration followed by HPLC. MALDI mass spectroscopy and Edman degradation determined the purity, Mr and sequence of the peptides, respectively. Three (BmP7, BmP8 and BmvP11) of them were homologues with the biologically active B. jararaca bradykinin potentiating peptides while the other with peptides or protein from different sources.
Export Options
About this article
Cite this article as:
Bourguignon C. S., Paes S. F., Calheiros B. E., Juliano M., Aguiar S. A., Melgarejo R. A. and Giovanni-De-Simone S., Bothrops Moojeni Venom Peptides Containing Bradykinin Potentiating Peptides Sequences, Protein & Peptide Letters 2001; 8 (1) . https://dx.doi.org/10.2174/0929866013409689
DOI https://dx.doi.org/10.2174/0929866013409689 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Two fACEs of the Tissue Renin-Angiotensin Systems: Implication in Cardiovascular Diseases
Current Pharmaceutical Design Current Options in the Treatment of Mast Cell Mediator-Related Symptoms in Mastocytosis
Inflammation & Allergy - Drug Targets (Discontinued) Hydrogen Sulfide as a New Endogenous Gaseous Transmitter in the Cardiovascular System
Current Vascular Pharmacology Pharmacological Potential of Exercise and RAS Vasoactive Peptides for Prevention of Diseases
Current Protein & Peptide Science Adrenomedullin and Nitric Oxide: Implications for the Etiology and Treatment of Primary Brain Tumors
CNS & Neurological Disorders - Drug Targets Low Doses of G-CSF Prevent Cerebral Infarction and Maintain Muscle Strength in an Experimental Model of Global Ischemic Stroke
Current Pharmaceutical Biotechnology Dural Venous Sinuses: What We Need to Know
Current Medical Imaging Women and Schizophrenia: Sex-Based Pharmacotherapy
Current Psychiatry Reviews Ghrelin and Cardiovascular Diseases
Current Cardiology Reviews Endotoxin Recognition Molecules MD-2 and Toll-like Receptor 4 as Potential Targets for Therapeutic Intervention of Endotoxin Shock
Current Drug Targets - Inflammation & Allergy Biochemical Markers for Brain Injury Monitoring in Children with or without Congenital Heart Diseases
CNS & Neurological Disorders - Drug Targets Antidote Control of Aptamer Therapeutics: The Road to a Safer Class of Drug Agents
Current Pharmaceutical Biotechnology Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract
Current Pharmaceutical Design Microbial Polysaccharides and their Derivatives as Current and Prospective Pharmaceuticals
Current Pharmaceutical Design Approaching Neurological Diseases to Reduce Mobility Limitations in Older Persons
Current Pharmaceutical Design A Review of Voltammetric Methods for Determination of Dopamine Agonists
Current Analytical Chemistry Opioid-induced Cardioprotection
Current Pharmaceutical Design Downregulation of Membrane-bound Angiotensin Converting Enzyme 2 (ACE2) Receptor has a Pivotal Role in COVID-19 Immunopathology
Current Drug Targets Is Nitric Oxide Assuming a Janus-Face in The Central Nervous System?
Current Medicinal Chemistry ENaC and Its Regulatory Proteins as Drug Targets for Blood Pressure Control
Current Drug Targets